Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene

Journal of Experimental and Clinical Cancer Research

Volumn 16, Issue 1, 1997, Pages 15-22

  Testorelli, C ^a   Bussini, S ^a   De Filippi, R ^b   Marelli, O ^a   Orlando, L ^c   Greiner, J W ^d   Grohmann, U ^e   Tentori, L ^c   Giuliani, A ^c,f   Bonmassar, E ^c,f,g   Graziani, G ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PERUGIA   (Italy)

^f CNR   (Italy)

^g LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

immunogenicity; K ras; leukemia; mutated oncogene; triazenes; xenogenization

Indexed keywords

DACARBAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSFECTION; IMMUNOGENICITY; LEUKEMIA; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DACARBAZINE; GENES, RAS; HISTOCOMPATIBILITY ANTIGENS CLASS I; LEUKEMIA L5178; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; TRANSFECTION;

EID: 12644289322     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Klein G., Boon T.: Tumor immunology: present perspectives. Curr. Opinion Tmmunol. 5: 687-692, 1993.
2. Bonmassar E., Bonmassar A., Vadlamudi S., Goldin A.: Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-Dimethyl-1-Triazeno)-Imidazole-4-Carboxamide. Cancer Res. 32: 1446-1450, 1972.
3. Giampietri A., Bonmassar A., Puccetti P., Circolo A., Goldin A., Bonmassar E.: Drug mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. Cancer Res. 41: 681-687, 1981.
4. 6-alkylguanine-DNA-alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res. 55: 6231-6236, 1995.
5. De Plaen E., Lurquin C., Van Pel A., Mariame B., Szikora J.P., Wolfel T., Sibille C., Chomez P. and Boon T.: Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc. Natl. Acad. Sci. USA 85: 2274-2281, 1988.
6. Campanile F., Houchens D.P., Gaston M., Goldin A., Bonmassar E.: Increased immunogenicity of two lymphoma lines after drug treatment of athymic (nude) mice. J. Natl. Cancer Inst. 55: 207-209, 1975.
7. Giampietri A., Fioretti M.C., Goldin A., Bonmassar E.: Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound. J. Natl. Cancer Inst. 64: 297-301, 1980.
8. Grohmann U., Puccetti P., Belladonna M.L., Fallarino F., Bianchi R., Binaglia L., Sagakuchi K, Mage M.G., Appella E., Fioretti M.C.: Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor. J. Immunol. 154: 4630-4641, 1995.
9. Melief C.J.M., Kast W.M.: Potential immunogenicity of oncogene and tumor suppressor gene products. Curr. Opinion Immunol. 5: 709-713, 1993.
10. Abrams S.I., Hand P.H., Tsang K.Y., Schlom J.: Mutant ras epitopes as targets for cancer vaccines. Sem. Oncol. 23: 118-134, 1996.
11. Abrams S.I., Stanziale S.E., Lunin S.D., Zaremba S., Schlom J.: Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell response. Eur. J. Immunol. 26: 435-443, 1996.
12. Nicolin A., Spreafico F., Bonmassar E., Goldin A.: Anti-genic changes of L5178Y lymphoma after treatment with 5-(3,3′-dimethyl-1-triazeno)imidazole-4-carboxamide in vivo. J. Natl. Cancer Inst. 56: 89-93, 1976.
13. Grohmann U., Puccetti P., Romani L., Binaglia L., Bianchi R., Belladonna M.L., Ullrich S.J., Appella E., Fioretti M.C.: Immunogenic tumor variants induced by drug treatment of the L5178Y lymphoma: search for serologycally defined antigens at the clonal level. Int. J. Cancer 52: 372-377, 1992.
14. Grohman U., Ullrich S.J., Mage M.G., Appella E., Fioretti M.C., Puccetti P., Romani L.: Identification and immunogenic properties of an 80 kDa surface antigen on a chemically xenogenized tumor: relationship to MuLV gp 70. Eur. J. Immunol. 20: 619-636, 1990.
15. Miller D.A. and Rosman G.J.: Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 980-986, 1989.
16. Chomczynski G.P., and Sacchi N.: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159, 1987.
17. Barbacid M.: Ras genes. Ann. Rev. Biochem 56: 799-827, 1987.
18. Boon T., Kellerman O.: Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc. Natl. Acad. Sci. USA 74: 272-275, 1977.
19. Schrier P.I., Peltenburg L.T.C.: Relationship between myc oncogene activation and MHC class I expression. Adv. Cancer Res. 60: 181-246, 1993.
20. Jung S., Schluesener J.: Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras protein. J. Exp. Med. 173: 273-276, 1991.
21. Fenton R.G., Taub D.D., Kwak L.W., Smith M.R., Longo D.L.: Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J. Natl. Cancer Inst. 85: 1294-1302, 1994.
22. Bos J.L.: Ras oncogenes in human cancers: a review. Cancer Res. 49: 4682-4689, 1989.
23. Romani L., Grohmann U., Fazioli F., Puccetti P., Mage M.G., Fioretti M.C.: Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. Cancer Immunol. Immunother. 26:48-54, 1988.